心血管疾病的铁死亡机制

doi:10.3969/j.issn.1003-9198.2025.09.020

Abstract

Abstract: Ferroptosis has become a research hotspot over the last 10 years. Unlike autophagy or necrosis, it is characterized by iron accumulation and lipotoxicity. It has been found that glutathione peroxidase 4 (GPX4), as a key protein of ferroptosis, is involved in the development of various cardiovascular diseases such as myocarditis. However, the mechanism of ferroptosis in various cardiovascular diseases remains unclear. In this article, we present the mechanisms of ferroptosis and its effects on various cells within the cardiac microenvironment, and investigate its significance in diverse cardiovascular diseases. Finally, we propose that targeting ferroptosis-related pathomechanisms may offer new hope for the treatment of related diseases.

Key words: ferroptosis, cardiovascular disease, lipid peroxidation, iron metabolism

CLC Number:

R 54

CHEN Yapeng, HU Jiawei, KONG Xiangquan, ZHANG Junjie. Mechanisms of ferroptosis in cardiovascular diseases[J]. Practical Geriatrics, 2025, 39(9): 957-962.

References

[1] ROTH G A, MENSAH G A, JOHNSON C O, et al. Globalburden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study[J]. J Am Coll Cardiol, 2020, 76(25): 2982-3021.
[2] XU W, LEE A L, LAM C L K, et al. Benefits and risks associated with statin therapy for primary prevention in old and very old adults: real-world evidence from a target trial emulation study[J]. Ann Intern Med, 2024, 177(6): 701-710.
[3] ABDELLATIF M, SCHMID S T, FUERLINGER A, et al. Anti-ageing interventions for the treatment of cardiovascular disease[J]. Cardiovasc Res, 2024: cvae177.
[4] DEL RE D P, AMGALAN D, LINKERMANN A, et al. Fundamental mechanisms of regulated cell death and implications for heart disease[J]. Physiol Rev, 2019, 99(4): 1765-1817.
[5] ZHENG J, CONRAD M. Ferroptosis: when metabolism meets cell death[J]. Physiol Rev, 2025, 105(2): 651-706.
[6] DIXON S J, LEMBERG K M, LAMPRECHT M R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072.
[7] QIN Y, QIAO Y, WANG D, et al. Ferritinophagy and ferroptosis in cardiovascular disease:mechanisms and potential applications[J]. Biomed Pharmacother, 2021, 141: 111872.
[8] HOU W, XIE Y, SONG X, et al. Autophagy promotes ferroptosis by degradation of ferritin[J]. Autophagy, 2016, 12(8): 1425-1428.
[9] KERINS M J, OOI A. The roles of NRF2 in modulating cellular iron homeostasis[J]. Antioxid Redox Signal, 2018, 29(17): 1756-1773.
[10] ANANDHAN A, DODSON M, SHAKYA A, et al. NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8[J]. Sci Adv, 2023, 9(5): eade9585.
[11] ZHAO Z. Hydroxyl radical generations form the physiologically relevant Fenton-like reactions[J]. Free Radic Biol Med, 2023, 208: 510-515.
[12] KAGAN V E, MAO G, QU F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis[J]. Nat Chem Biol, 2017, 13(1): 81-90.
[13] KOPPULA P, ZHUANG L, GAN B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy[J]. Protein Cell, 2021, 12(8): 599-620.
[14] LEWERENZ J, HEWETT S J, HUANG Y, et al. The cystine/glutamate antiporter system x(c) (-) in health and disease: from molecular mechanisms to novel therapeutic opportunities[J]. Antioxid Redox Signal, 2013, 18(5): 522-555.
[15] KOPPULA P, ZHANG Y, ZHUANG L, et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer[J]. Cancer Commun:Lond, 2018, 38(1): 12.
[16] TRIMM E, RED-HORSE K. Vascular endothelial cell development and diversity[J]. Nat Rev Cardiol, 2023, 20(3): 197-210.
[17] XU S, ILYAS I, LITTLE P J, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies[J]. Pharmacol Rev, 2021, 73(3): 924-967.
[18] BAI T, LI M, LIU Y, et al. Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell[J]. Free Radic Biol Med, 2020, 160: 92-102.
[19] MA H, HUANG Y, TIAN W, et al. Endothelial transferrin receptor 1 contributes to thrombogenesis through cascade ferroptosis[J]. Redox Biol, 2024, 70: 103041.
[20] QIN X, ZHANG J, WANG B, et al. Ferritinophagy is involved in the zinc oxide nanoparticles-induced ferroptosis of vascular endothelial cells[J]. Autophagy, 2021, 17(12): 4266-4285.
[21] MIANO J M, FISHER E A, MAJESKY M W. Fate and state of vascular smooth muscle cells in atherosclerosis[J]. Circulation, 2021, 143(21): 2110-2116.
[22] YE Y, CHEN A, LI L, et al. Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification[J]. Kidney Int, 2022, 102(6): 1259-1275.
[23] ZHANG F, LI K, ZHANG W, et al. Ganglioside GM3 protects against abdominal aortic aneurysm by suppressing ferroptosis[J]. Circulation, 2024, 149(11): 843-859.
[24] SUN D Y, WU W B, WU J J, et al. Pro-ferroptotic signaling promotes arterial aging via vascular smooth muscle cell senescence[J]. Nat Commun, 2024, 15(1): 1429.
[25] FANG X, ARDEHALI H, MIN J, et al. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease[J]. Nat Rev Cardiol, 2023, 20(1): 7-23.
[26] WANG X, CHEN X, ZHOU W, et al. Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways[J]. Acta Pharm Sin B, 2022, 12(2): 708-722.
[27] WANG B, JIN Y, LIU J, et al. EP1 activation inhibits doxorubicin-cardiomyocyte ferroptosis via Nrf2[J]. Redox Biol, 2023, 65: 102825.
[28] CAI W, LIU L, SHI X, et al. Alox15/15-HpETE aggravates myocardial ischemia-reperfusion injury by promoting cardiomyocyte ferroptosis[J]. Circulation, 2023, 147(19): 1444-1460.
[29] KONG P, CUI Z Y, HUANG X F, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention[J]. Signal Transduct Target Ther, 2022, 7(1): 131.
[30] DAMLUJI A A, VAN DIEPEN S, KATZ J N, et al. Mechanical complications of acute myocardial infarction: a scientific statement from the American Heart Association[J]. Circulation, 2021, 144(2): e16-e35.
[31] PARK T J, PARK J H, LEE G S, et al. Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes[J]. Cell Death Dis, 2019, 10(11): 835.
[32] YU Q, ZHANG N, GAN X, et al. EGCG attenuated acute myocardial infarction by inhibiting ferroptosis via miR-450b-5p/ACSL4 axis[J]. Phytomedicine, 2023, 119: 154999.
[33] MIAO M, CAO S, TIAN Y, et al. Potential diagnostic biomarkers: 6 cuproptosis- and ferroptosis-related genes linking immune infiltration in acute myocardial infarction[J]. Genes Immun, 2023, 24(4): 159-170.
[34] XIANG Q, YI X, ZHU X H, et al. Regulated cell death in myocardial ischemia-reperfusion injury[J]. Trends Endocrinol Metab, 2024, 35(3): 219-234.
[35] TANG L J, LUO X J, TU H, et al. Ferroptosis occurs in phase of reperfusion but not ischemia in rat heart following ischemia or ischemia/reperfusion[J]. Naunyn Schmiedebergs Arch Pharmacol, 2021, 394(2): 401-410.
[36] DODSON M, CASTRO-PORTUGUEZ R, ZHANG D D. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis[J]. Redox Biol, 2019, 23: 101107.
[37] XU S, WU B, ZHONG B, et al. Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2)/System xc-/glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis[J]. Bioengineered, 2021, 12(2): 10924-10934.
[38] MOE G W, MARÍN-GARCÍA J. Role of cell death in the progression of heart failure[J]. Heart Fail Rev, 2016, 21(2): 157-167.
[39] HAN Q, SHI J, YU Y, et al. Calycosin alleviates ferroptosis and attenuates doxorubicin-induced myocardial injury via the Nrf2/SLC7A11/GPX4 signaling pathway[J]. Front Pharmacol, 2024, 15: 1497733.
[40] LI N, JIANG W, WANG W, et al. Ferroptosis and its emerging roles in cardiovascular diseases[J]. Pharmacol Res, 2021, 166: 105466.
[41] RUAN Y, ZHANG L, ZHANG L, et al. Therapeutic approaches targeting ferroptosis in cardiomyopathy[J]. Cardiovasc Drugs Ther, 2025, 36(3):595-613.
[42] TANG Z, HUANG X, MEI H, et al. Silencing of METTL3 suppressed ferroptosis of myocardial cells by m6A modification of SLC7A11 in a YTHDF2 manner[J]. J Bioenerg Biomembr, 2024, 56(2): 149-157.
[43] GU J J, DU T J, ZHANG L N, et al. Identification of ferroptosis-related genes in heart failure induced by transverse aortic constriction[J]. J Inflamm Res, 2023, 16: 4899-4912.
[44] WANG M, MO D, ZHANG N, et al. Ferroptosis in diabetic cardiomyopathy: advances in cardiac fibroblast-cardiomyocyte interactions[J]. Heliyon, 2024, 10(15): e35219.
[45] SONG Z, WANG J, ZHANG L. Ferroptosis: a new mechanism in diabetic cardiomyopathy[J]. Int J Med Sci, 2024, 21(4): 612-622.
[46] ZHUANG S, MA Y, ZENG Y, et al. METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1OT1-miR-7-5p-TFRC axis[J]. Cell Biol Toxicol, 2023, 39(3): 1015-1035.

Mechanisms of ferroptosis in cardiovascular diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Metrics

Recommended 10

[1]	GAO Ying, LIANG Wei. Advances in the study of sarcopenic obesity and cardiovascular disease [J]. Practical Geriatrics, 2025, 39(7): 732-736.
[2]	ZHU Xiangyu, HANG Lejia, WANG Yu, WU Yuyi, ZHAO Yijing, ZHU Bei, HUANG Jingjing. Advances in artificial intelligence for cardiovascular disease in the elderly [J]. Practical Geriatrics, 2025, 39(6): 621-625.
[3]	ZHENG Hui, WANG Hui, YIN Donghua, YIN Hongli, SUN Chuqiao,CHENG Yang, WANG Ying. Analysis of the correlation between obesity-related indices and risk of cardiovascular disease in postmenopausal women [J]. Practical Geriatrics, 2025, 39(4): 372-376.
[4]	FAN Yao, WANG Qiang, TANG Ji-hong, LOU Qing-lin, TANG Wei, GU Liu-bao. Analysis of genomic DNA methylation of peripheral blood in elderly patients with type 2 diabetes mellitus suffering form cardiovascular disease-induced death [J]. Practical Geriatrics, 2022, 36(5): 468-472.
[5]	FAN Tian-shu, ZHAO Wen-xue, LU Miao, WANGXiang-ming, ZHA Zhi-min, CAO Ya-ru, GUO Yan. Correlation between sarcopenia and non-enzymatic glycosylation and cardiovascular disease in the community elderly [J]. Practical Geriatrics, 2021, 35(9): 910-913.
[6]	ZHU Jian-Yi, LV Zhi-Gang, SHI Heng-Chuan. Relationship of serum total homocysteine and macrovascular diseases in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2010, 24(2): 135-137.